Comparing two chemo combos for stage III stomach cancer after surgery
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have been diagnosed with stomach or gastroesophageal junction adenocarcinoma (confirmed by biopsy)
- You have had a standard D2 gastrectomy (surgery) that removed all visible cancer (R0 resection) without receiving chemotherapy or radiation before surgery
- Your cancer is stage IIIA, IIIB, or IIIC (according to AJCC staging) and has Lauren classification
- You are in good physical condition (able to carry out daily activities, ECOG 0–1) and your organs (bone marrow, liver, kidneys) work well enough to handle treatment
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
This trial tests adding disitamab vedotin (a drug that targets HER2) to standard chemotherapy (SOX) after surgery for stage 3 stomach cancer. The goal is to see if the combination works better than chemo alone to prevent cancer from coming back.
Hear when a new Adjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.